Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Bilateral breast carcinoma and local recurrence: prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample].

Bremer M, Steinmann D, Dörk T, Börger J, Rades D, Karstens JH.

Strahlenther Onkol. 2001 Jul;177(7):325-9. German.

PMID:
11505617
2.

Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.

Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dörk T.

Br J Cancer. 2001 Sep 14;85(6):850-8.

3.

BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.

Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG.

J Clin Oncol. 1999 Oct;17(10):3017-24.

PMID:
10506595
4.

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.

Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.

5.

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R.

Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25.

PMID:
27225387
6.

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative Group.

Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.

7.

Breast cancer treatment in mutation carriers: surgical treatment.

Biglia N, D'Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E.

Minerva Ginecol. 2016 Oct;68(5):548-56. Epub 2016 Jan 28. Review.

8.

Total skin-sparing mastectomy in BRCA mutation carriers.

Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ.

Ann Surg Oncol. 2014 Jan;21(1):37-41. doi: 10.1245/s10434-013-3230-0. Epub 2013 Aug 28.

PMID:
23982256
9.

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H.

Br J Cancer. 2000 Sep;83(6):737-42.

10.

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.

PMID:
16140006
11.

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.

Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group.

Breast Cancer Res Treat. 2010 Sep;123(2):491-8. doi: 10.1007/s10549-010-0769-3. Epub 2010 Feb 5.

12.

Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.

Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, Mirocha J, Amersi F, Giuliano AE.

Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.

PMID:
25047471
13.

Breast cancer following ovarian cancer in BRCA mutation carriers.

Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.

JAMA Surg. 2014 Dec;149(12):1306-13. doi: 10.1001/jamasurg.2014.1081. Erratum in: JAMA Surg. 2015 Feb;150(2):183.

PMID:
25372568
14.

Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.

Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group.

Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22.

PMID:
30350268
15.

Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.

Ibrahim SS, Hafez EE, Hashishe MM.

J Exp Clin Cancer Res. 2010 Jun 25;29:82. doi: 10.1186/1756-9966-29-82.

17.

Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.

Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.

18.

BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.

Kim S, Rimm D, Carter D, Khan A, Parisot N, Franco MA, Bale A, Haffty BG.

Breast J. 2003 May-Jun;9(3):167-74.

PMID:
12752624
19.

Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.

Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E.

BMC Cancer. 2017 Jun 21;17(1):438. doi: 10.1186/s12885-017-3422-2.

20.

Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.

Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW, Lau S, Andrulis IL, Ozcelik H.

Hum Mutat. 2000 Jul;16(1):88-9.

PMID:
10874312

Supplemental Content

Support Center